Syngene International Yönetim

Yönetim kriter kontrolleri 2/4

Syngene International CEO'su Jonathan Hunt, Jan2016 tarihinde atandı, in görev süresi 8.83 yıldır. in toplam yıllık tazminatı ₹ 285.33M olup, şirket hissesi ve opsiyonları dahil olmak üzere 50% maaş ve 50% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.062% ine doğrudan sahiptir ve bu hisseler ₹ 215.40M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.1 yıl ve 5.3 yıldır.

Anahtar bilgiler

Jonathan Hunt

İcra Kurulu Başkanı

₹285.3m

Toplam tazminat

CEO maaş yüzdesi	50.0%
CEO görev süresi	8.8yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	6.1yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jonathan Hunt'un ücretlendirmesi Syngene International'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹5b
Jun 30 2024	n/a	n/a	₹5b
Mar 31 2024	₹285m	₹143m	₹5b
Dec 31 2023	n/a	n/a	₹5b
Sep 30 2023	n/a	n/a	₹5b
Jun 30 2023	n/a	n/a	₹5b
Mar 31 2023	₹85m	₹85m	₹5b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹4b
Jun 30 2022	n/a	n/a	₹4b
Mar 31 2022	₹76m	₹76m	₹4b
Dec 31 2021	n/a	n/a	₹4b
Sep 30 2021	n/a	n/a	₹4b
Jun 30 2021	n/a	n/a	₹4b
Mar 31 2021	₹65m	₹65m	₹4b
Dec 31 2020	n/a	n/a	₹4b
Sep 30 2020	n/a	n/a	₹4b
Jun 30 2020	n/a	n/a	₹4b
Mar 31 2020	₹66m	₹66m	₹4b
Dec 31 2019	n/a	n/a	₹4b
Sep 30 2019	n/a	n/a	₹4b
Jun 30 2019	n/a	n/a	₹3b
Mar 31 2019	₹90m	₹47m	₹3b
Dec 31 2018	n/a	n/a	₹3b
Sep 30 2018	n/a	n/a	₹3b
Jun 30 2018	n/a	n/a	₹3b
Mar 31 2018	₹94m	₹47m	₹3b

Tazminat ve Piyasa: Jonathan 'nin toplam tazminatı ($USD 3.39M ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 590.32K ).

Tazminat ve Kazançlar: Jonathan şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Jonathan Hunt (55 yo)

8.8yrs

Görev süresi

₹285,330,000

Tazminat

Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jonathan Hunt	MD, CEO & Executive Director	8.8yrs	₹285.33m	0.062% ₹ 215.4m
Sibaji Biswas	CFO & Executive Director	4.9yrs	₹34.14m	0.030% ₹ 103.8m
Jayashree Aiyar	Chief Scientific Officer	less than a year	Veri yok	0% ₹ 0
Krishnan G	Head of Investor Relations	no data	Veri yok	0.0016% ₹ 5.4m
Priyadarshini Mahapatra	Head of Legal	5.3yrs	₹4.72m	0.0024% ₹ 8.3m
Sandeep Nair	Head of Corporate Communications	no data	Veri yok	Veri yok
Andrew Webster	Chief Human Resources Officer	1.9yrs	Veri yok	Veri yok
Dhananjay Patankar	Head of Pharmaceutical & Biopharmaceutical Development	no data	₹10.80m	Veri yok
Purushottam Singnurkar	Head of Formulations Development	no data	₹5.50m	0.025% ₹ 86.9m
Ajit Manocha	Head of IT	8.8yrs	Veri yok	0.00038% ₹ 1.3m
Chetan Tamhankar	Head of Clinical Development & Stability Studies	8.8yrs	Veri yok	0.0060% ₹ 20.9m
Rajendra Patil	Head of EHSS	6.8yrs	Veri yok	0.0093% ₹ 32.6m

6.1yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 539268 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jonathan Hunt	MD, CEO & Executive Director	7.5yrs	₹285.33m	0.062% ₹ 215.4m
Sibaji Biswas	CFO & Executive Director	less than a year	₹34.14m	0.030% ₹ 103.8m
Catherine Rosenberg	Non-Executive Director	24.3yrs	₹8.28m	0.0022% ₹ 7.6m
Kiran Mazumdar-Shaw	Non-Executive Chairperson	no data	₹9.43m	0.0055% ₹ 19.1m
Vinita Bali	Lead Independent Director	7.3yrs	₹8.62m	Veri yok
Vijay Kuchroo	Independent Director	7.7yrs	₹7.46m	0.012% ₹ 43.5m
Nilanjan Roy	Additional Independent Director	less than a year	Veri yok	Veri yok
Kush Parmar	Independent Non Executive Director	3.4yrs	₹6.47m	Veri yok
Manja Boerman	Independent Director	less than a year	Veri yok	Veri yok
Sharmila Karve	Additional Independent Director	5.3yrs	₹8.46m	Veri yok

5.3yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 539268 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Syngene International Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insider recently sold ₹7.0m worth of stock

CFO & Executive Director recently sold ₹32m worth of stock

Syngene International Limited Announces CFO Changes

Insider recently sold ₹6.0m worth of stock

MD, CEO & Executive Director recently sold ₹115m worth of stock

Head of Formulations Development recently sold ₹9.6m worth of stock

Recent updates

Insider recently sold ₹7.0m worth of stock

CFO & Executive Director recently sold ₹32m worth of stock

Price target increased by 8.9% to ₹836

Second quarter 2025 earnings: EPS exceeds analyst expectations

Syngene International Limited Announces CFO Changes

Syngene International Limited to Report Q2, 2025 Results on Oct 23, 2024

Insider recently sold ₹6.0m worth of stock

MD, CEO & Executive Director recently sold ₹115m worth of stock

Head of Formulations Development recently sold ₹9.6m worth of stock

Syngene International Limited Approves Final Dividend for the Financial Year Ended March 31, 2024

Syngene International Limited Approves for the Financial Year Ended March 31, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Syngene International Limited Proposes Final Dividend for the Financial Year Ended March 31, 2024

Syngene International Limited to Report Q1, 2025 Results on Jul 24, 2024

New minor risk - Insider selling

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹4.9m worth of stock

Dividend of ₹1.25 announced

Syngene International Limited, Annual General Meeting, Jul 24, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Syngene International Limited Recommends Final Dividend for the Financial Year 2024

Syngene International Limited to Report Q4, 2024 Results on Apr 24, 2024

Head of IT recently sold ₹1.5m worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024

Insider recently sold ₹9.9m worth of stock

Syngene International Limited to Report Q3, 2024 Results on Jan 25, 2024

Head of Investor Relations recently sold ₹1.7m worth of stock

Head of Investor Relations recently sold ₹1.8m worth of stock

Insider recently sold ₹7.1m worth of stock

Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024

Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director

Second quarter 2024 earnings released: EPS: ₹2.90 (vs ₹2.55 in 2Q 2023)

Syngene International Limited Announces Retirement of Joydeep Kant as Sr. Vice President - Development Services, Effective October 31, 2023

Syngene International Limited to Report Q2, 2024 Results on Oct 17, 2023

Chief Financial Officer recently sold ₹57m worth of stock

Insider recently sold ₹2.4m worth of stock

Price target increased by 8.9% to ₹808

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of ₹1.25 per share at 0.1% yield

Insider recently sold ₹2.3m worth of stock

MD, CEO & Executive Director recently sold ₹166m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹2.1m worth of stock

Insider recently sold ₹4.6m worth of stock

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.9m worth of stock

Syngene International Limited Confirms Financial Guidance for Fiscal 2023

Third quarter 2023 earnings released: EPS: ₹2.74 (vs ₹2.57 in 3Q 2022)

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.4m worth of stock

Insider recently sold ₹1.0m worth of stock

Insider recently sold ₹7.8m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹4.3m worth of stock

Syngene International Limited Provides Earnings Guidance for the Year 2022

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹1.1m worth of stock

MD, CEO & Executive Director recently sold ₹20m worth of stock

Chief Human Resources Officer recently sold ₹13m worth of stock

Insider recently sold ₹4.0m worth of stock

Syngene International Limited Approves the Additional Special Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syngene International Limited, Annual General Meeting, Jul 20, 2022

Upcoming dividend of ₹1.00 per share

Syngene International Limited Recommends Special Additional Dividend for the Financial Year Ended March 31, 2022

Insider recently sold ₹1.7m worth of stock

Syngene International Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022